Press Releases

Medco Health Solutions, Inc. (NYSE: MHS) and United BioSource Corporation (UBC) today announced a definitive agreement under which Medco will acquire closely held UBC in an all-cash transaction valued at approximately $730 million. The combination of America’s leading advanced pharmacy with one of the world’s most respected sources of post-approval drug and device research extends Medco’s core capabilities in data analytics and research to further accelerate pharmaceutical knowledge – advancing patient safety and furthering evidence-based medicine.

United BioSource Corporation (UBC), a global scientific and medical affairs organization, today announced that it had secured a new line of credit that provides the company with up to $150 million in additional financing for acquisitions and other significant growth investments. Wells Fargo, PNC Bank, Capital One and JPMorgan Chase participated in financing the new credit facility.

The International Working Group for Health Technology Assessment Advancement today announced the publication of a new article, “EBM, HTA, and CER: Clearing the Confusion,” in the journal The Milbank Quarterly. The article clarifies a range of terms commonly used by health care and policy experts, including evidence-based medicine (EBM), health technology assessment (HTA), and comparative effectiveness research (CER).

United BioSource Corporation (UBC) today announced the launch of a new office in Lörrach, Germany, further expanding the company’s clinical research and medical affairs capabilities in Europe. The Lörrach office is located near Basel, Switzerland and is the 10th UBC office to open in Europe, adding to facilities in the United Kingdom, Switzerland, Ukraine, Spain, Sweden, Hungary and the Czech Republic.

United BioSource Corporation (UBC) today announced results from an independent survey that examined late phase product development services delivered by 34 contract research organizations and other scientific and medical affairs companies serving the biopharmaceutical industry. The report, titled 2010 Late Phase Market Dynamics and published by Industry Standard Research (ISR), provided data and analysis from a survey that captured information from 149 respondents, representing 95 companies.

United BioSource Corporation (UBC) today announced the acquisition of Abt Bio-Pharma Solutions, Inc. (ABS), a Boston, Massachusetts-based provider of health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries. The acquisition of ABS is part of UBC’s ongoing strategy to build a “best in class” portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies.

Clearstate Pte. Ltd. and United BioSource Corporation (UBC) today announced a strategic partnership to provide global market access, pricing and reimbursement strategies for manufacturers of biopharmaceuticals, medical devices, and other medical technology.

United BioSource Corporation today announced that Dr. Gretchen Dieck has joined the company as Vice President, Safety, Epidemiology & Risk Management. Dr. Dieck is UBC's latest addition to their roster of biopharmaceutical safety experts. Dr. Dieck joins UBC from Pfizer Inc, where she held positions of increasing responsibility for the last 23 years. Most recently, Dr. Dieck was Pfizer's senior executive responsible for safety and risk management for the company's entire portfolio of biopharmaceuticals. In this capacity, Dr Dieck led all aspects of biopharmaceutical safety and risk management, from initial human research through regulatory approval and marketing.

United BioSource Corporation (UBC) today announced the opening of its newest global office in Tokyo, Japan. The UBC office will be led by Kumpei Kobayashi, PharmD, a biopharmaceutical industry veteran with over 20 years of product development experience throughout the Asia-Pacific region.

United BioSource Corporation today announced that Berkshire Partners LLC, a Boston-based private equity firm, has made a $125 million growth equity investment to support the Company's evidence-based acquisition and service offering expansion strategy.

United BioSource Corporation (UBC) announces the expansion of its pricing and reimbursement capabilities with the appointment of two senior strategists in their London, United Kingdom office as part of its wider focus to offer its clients an integrated and comprehensive suite of worldwide market access solutions.

United BioSource Corporation (UBC) today announced the acquisition of Gigamoto Technology Partners, Inc. (Gigamoto), a Pennsylvania-based software development company providing leading-edge technology solutions in support of drug safety and risk management programs for the life sciences industry. The acquisition is part of UBC's strategy of building integrated capabilities in risk management and drug safety by combining leading-edge technology with world class scientific, consulting and operational expertise.

United BioSource Corporation (UBC) today announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas, validated in over 60 languages, and cited in more than 700 publications and abstracts. Additionally, CDR maintains the industry’s largest healthy subject, patient, and drug databases of cognitive effects, providing the standard for establishing the clinical relevance of compounds.

United BioSource Corporation (UBC) announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has joined its European Scientific Advisory Board for CNS Clinical Trials. Professor Winblad is one of the world’s leading Alzheimer’s disease researchers and currently serves as Professor of Geriatric Medicine and Chief Physician at the Karolinska University Hospital, Huddinge, and the Karolinska Institute in Stockholm, Sweden.

United BioSource Corporation (UBC) today announced the acquisition of HPM (Geneva) SA, a Geneva, Switzerland-based provider of drug safety and pharmacovigilance services, further extending UBC's reach into the European market. The acquisition of HPM (Healthcare Project Management) represents a strategic expansion of UBC's market-leading safety and risk management services, which include comprehensive safety reporting, case processing, and integrated pharmacovigilance services.

United BioSource Corporation (UBC) announces the formation of the Center for Epidemiology and Database Analytics (CEDA). As the demand for epidemiologic and database expertise escalates spurred by an ever-increasing need for evidence-driven solutions, the creation of a dedicated center for our expert team allows UBC to provide even more comprehensive solutions for our clients.